title: Flexibility and applicability of β-expectation tolerance interval approach to assess the fitness of purpose of pharmaceutical analytical methods.
abstract: An innovative versatile strategy using Total Error has been proposed to decide about the method's validity that controls the risk of accepting an unsuitable assay together with the ability to predict the reliability of future results. This strategy is based on the simultaneous combination of systematic (bias) and random (imprecision) error of analytical methods. Using validation standards, both types of error are combined through the use of a prediction interval or β-expectation tolerance interval. Finally, an accuracy profile is built by connecting, on one hand all the upper tolerance limits, and on the other hand all the lower tolerance limits. This profile combined with pre-specified acceptance limits allows the evaluation of the validity of any quantitative analytical method and thus their fitness for their intended purpose. In this work, the approach of accuracy profile was evaluated on several types of analytical methods encountered in the pharmaceutical industrial field and also covering different pharmaceutical matrices. The four studied examples depicted the flexibility and applicability of this approach for different matrices ranging from tablets to syrups, different techniques such as liquid chromatography, or UV spectrophotometry, and for different categories of assays commonly encountered in the pharmaceutical industry i.e. content assays, dissolution assays, and quantitative impurity assays. The accuracy profile approach assesses the fitness of purpose of these methods for their future routine application. It also allows the selection of the most suitable calibration curve, the adequate evaluation of a potential matrix effect and propose efficient solution and the correct definition of the limits of quantification of the studied analytical procedures.
authors.affiliation: Analytical Chemistry Laboratory, CIRM, Institute of Pharmacy, University of Liège, Belgium.
authors.forename: A
authors.initials: A
authors.lastname: Bouabidi
authors.forename: M
authors.initials: M
authors.lastname: Talbi
authors.forename: H
authors.initials: H
authors.lastname: Bourichi
authors.forename: A
authors.initials: A
authors.lastname: Bouklouze
authors.forename: M
authors.initials: M
authors.lastname: El Karbane
authors.forename: B
authors.initials: B
authors.lastname: Boulanger
authors.forename: Y
authors.initials: Y
authors.lastname: Brik
authors.forename: Ph
authors.initials: P
authors.lastname: Hubert
authors.forename: E
authors.initials: E
authors.lastname: Rozet
mesh_terms: D000658:Amoxicillin / Q000032:analysis; D015982:Bias; D002138:Calibration; D002626:Chemistry, Pharmaceutical; D002851:Chromatography, High Pressure Liquid; D004304:Dosage Forms; D004340:Drug Contamination; D015725:Fluconazole / Q000032:analysis; D057230:Limit of Detection; D016014:Linear Models; D008687:Metformin / Q000032:analysis; D015233:Models, Statistical; D010226:Parabens / Q000032:analysis; D004364:Pharmaceutical Preparations / Q000032:analysis*; D012015:Reference Standards; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet; D013678:Technology, Pharmaceutical / Q000379:methods* / Q000592:standards
chemical_list: D004304:Dosage Forms; D010226:Parabens; D004364:Pharmaceutical Preparations; D000658:Amoxicillin; D015725:Fluconazole; D008687:Metformin; C038193:4-hydroxybenzoic acid